Currently Autolus manufactures its product candidates at the Cell and Gene Therapy Catapult manufacturing facility in the UK.
For commercial supply, Autolus has built a new 70,000 square foot commercial manufacturing facility, The Nucleus, in Stevenage, UK. Key equipment installation and validation were completed by Autolus in Q1 2023, enabling operational engineering trials to commence in Q2 2023. Activities are on track for the commencement of further BLA enabling GMP operations in the second half of 2023. The facility has been designed to manufacture and test approximately 2,000 batches per year with expansion opportunities.